Recent studies also report increased expression of OTUB1 in prostate, colorectal, and breast cancers that are associated with poor survival, high metastatic potential, and chemotherapeutic drug resistance (Liu et al, 2014; Zhou et al, 2014; Iglesias‐Gato et al, 2015; Karunarathna et al, 2015). Here, OTUB1 is linked to breast cancer.